A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency To evaluate the efficacy of monthly replacement therapy with rFXIII on prevention of bleeding episodes in subjects with congenital FXIII deficiency.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec or liraglutide alone, in subjects with type 2 iabetes treated with 1-2 oral anti-diabetic drugs (OADs) To confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in subjects with type 2 diabetes. This is done by comparing the difference in change in HbA1c from baseline after 26 ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in combination with metformin and glimepiride in insulin naïve subjects with type 2 diabetes. Trial Phase: 4 To investigate if biphasic insulin aspart (BIAsp) 30 once daily (OD) in combination with metformin and glimepiride is non-inferior and superior in the event of non-inferiority, compared with insulin g...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin in subjects with type 1 diabetes To confirm the efficacy of SIBA + insulin aspart in controlling glycaemia with respect to change from baseline in HbA1c after 52 weeks of treatment. This is done by comparing the difference in change ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients born with Haemophilia and having Inhibitors To demonstrate the efficacy of NNC 0078-0000-0007 in controlling acute bleeding episodes in patients with haemophilia and inhibitors.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomised, multicentric, open labelled, parallel group trial with insulin aspart and insulin detemir, investigating the glycaemic effect and profile in children with Type 1 diabetes, of two separate Levemir® + NovoRapid® injections and extemporaneous mixing. THE Paediatric MIXING TRIAL The primary objective of the trial is to assess if using insulin detemir mixed with insulin aspart in the same syringe and 2 separates injections of insulin detemir and insulin aspart will have any cl...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Determir versus Glargine for weight gain in adolescents with type 1 diabetes Background and study aims Diabetes is a life-long condition where a person is unable to control their blood sugar levels. here are two main types of diabetes. In type 1 diabetes the body is unable to ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults with Type 1 Diabetes To investigate the pharmacokinetic total exposure of SIBA in children, adolescents and adult subjects with type 1 diabetes

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 years with Type 1 Diabetes on a Basal- Bolus Regimen with Insulin Aspart as Bolus Insulin Trial Phase: 3b •To study the development of insulin detemir-insulin aspart cross-reacting antibodies following a 104 week-period (52 weeks in NN304-1689 and 52 weeks in NN304-1690) of insulin detemir treatment in ch...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efecto de liraglutida en el peso corporal en sujetos con sobrepeso u obesos con diabetes tipo 2. Ensayo clínico de 1 año de duración, aleatorizado, doble-ciego, controlado con placebo, con tres grupos paralelos, multicéntrico, multinacional, con un periodo de seguimiento observacional de 12 semanas To investigate the efficacy of liraglutide compared to liraglutide placebo in inducing and maintaining weight loss in overweight or obese subjects with type 2 diabetes after 52 weeks

• Pays Aucun
• Organes Aucun
• Spécialités Aucune